Open AccessAnticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines
Author(s) -
Truman J. Milling,
Majed A. Refaai,
Neil Sengupta
Publication year - 2021
Publication title -
digestive diseases and sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 124
eISSN - 1573-2568
pISSN - 0163-2116
DOI - 10.1007/s10620-020-06728-y
Subject(s) - medicine , anticoagulant , prothrombin complex concentrate , warfarin , hemostasis , guideline , intensive care medicine , gastrointestinal bleeding , dabigatran , coagulopathy , coagulation testing , coagulation , atrial fibrillation , pathology
Patients receiving anticoagulant therapies, such as vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), commonly experience gastrointestinal (GI) bleeding as a complication and may require anticoagulant reversal prior to endoscopic treatment. Anticoagulant reversal agents include prothrombin complex concentrates (PCCs; including 3 or 4 coagulation factors), plasma, vitamin K, and target-specific DOAC reversal agents (e.g., idarucizumab and andexanet alfa).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom